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Abstract
Background: The present study aimed to evaluate a hypothetical Leishmania amastigote-specific protein (LiHyp1),
previously identified by an immunoproteomic approach performed in Leishmania infantum, which showed homology to the
super-oxygenase gene family, attempting to select a new candidate antigen for specific serodiagnosis, as well as to
compose a vaccine against VL.
Methodology/Principal Findings: The LiHyp1 DNA sequence was cloned; the recombinant protein (rLiHyp1) was purified
and evaluated for its antigenicity and immunogenicity. The rLiHyp1 protein was recognized by antibodies from sera of
asymptomatic and symptomatic animals with canine visceral leishmaniasis (CVL), but presented no cross-reactivity with sera
of dogs vaccinated with Leish-Tec, a Brazilian commercial vaccine; with Chagas’ disease or healthy animals. In addition, the
immunogenicity and protective efficacy of rLiHyp1 plus saponin was evaluated in BALB/c mice challenged subcutaneously
with virulent L. infantum promastigotes. rLiHyp1 plus saponin vaccinated mice showed a high and specific production of
IFN-c, IL-12, and GM-CSF after in vitro stimulation with the recombinant protein. Immunized and infected mice, as compared
to the control groups (saline and saponin), showed significant reductions in the number of parasites found in the liver,
spleen, bone marrow, and in the paws’ draining lymph nodes. Protection was associated with an IL-12-dependent
production of IFN-c, produced mainly by CD4 T cells. In these mice, a decrease in the parasite-mediated IL-4 and IL-10
response could also be observed.
Conclusions/Significance: The present study showed that this Leishmania oxygenase amastigote-specific protein can be
used for a more sensitive and specific serodiagnosis of asymptomatic and symptomatic CVL and, when combined with a
Th1-type adjuvant, can also be employ as a candidate antigen to develop vaccines against VL.
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Introduction
Visceral leishmaniasis (VL) caused by Leishmania donovani and L.
infantum/L. chagasi represents an important disease in the world,
leading to nearly 500,000 new cases and 50,000 deaths annually.
The first choice of treatment for all forms of leishmaniasis is still
based on the use of the parenteral administration of pentavalent
antimonials; however, increased parasite resistance and several
side effects reported by patients have been important problems
[1,2]. Liposomal amphotericin B is effective but is too expensive
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for most patients [3]. Results from clinical trials using oral
miltefosine are encouraging; however, therapy is linked to both
potential toxicity and teratogenicity, and should not be given to
childbearing-age women [4]. Therefore, the development of new
strategies to prevent leishmaniasis has become a high priority.
The evidence of life-long immunity to leishmaniasis has inspired
the development of prophylactic vaccination protocols against the
disease, but few have progressed beyond the experimental stage.
Most experimental vaccines have focused on the mouse model for
cutaneous leishmaniasis. Several studies have demonstrated the
Type-1 cells mediated immunity-dependence for protective
responses against disease. Moreover, Th1 cells response has also
been correlated with protection against VL [5]. In this context, the
protective immunity in murine VL primarily depends on an IL-12-
driven Th1 cells response, leading to an increased IL-2 and IFN-c
production. Substantial uptake of inducible NO syntase by IFN-c
generates NO from splenic and liver cells, thereby controlling
parasite multiplication in these organs [6,7]. By contrast, TGF-b,
IL-10, and IL-13 represent major disease promoting cytokines,
leading in turn to the suppression of the Th1 response [8]. Low
levels of IL-4 commonly enhance vaccine-induced protection by
indirectly increasing IFN-c production by T cells [9].
In recent decades, the majority of studies have focused on
Leishmania promastigote antigens for vaccine development
[10,11,12,13]; however, amastigote antigens also seem to be
appropriate targets for the immune responses elicited by vaccines,
given that after a few hours of infection and during the active
disease, this parasite stage becomes exposed to the host immune
system [14]. In addition, the fact that promastigotes can be easily
cultured in vitro, as opposed to axenic amastigotes, has hampered
the identification of amastigote-specific stage antigens [15].
In the present work, a hypothetical amastigote-specific L.
infantum protein, LiHyp1 (XP_0014689 41.1), which has been
identified by an immunoproteomic approach, was recognized by
antibodies present in sera samples of dogs with asymptomatic and
symptomatic VL [16]. The amastigote-specific Leishmania protein
gene (LiHyp1) is predicted to encode a protein with a theoretical
molecular weight of 36.6 kDa. An in silico sequence comparison
revealed that LiHyp1 belongs to the super-oxygenase family in
Leishmania, and is an alkylated DNA repair protein. The ability of
the recombinant protein (rLiHyp1) to induce protection against
infection with virulent L. infantum promastigotes was assessed in
BALB/c mice. The results showed that rLiHyp1 was antigenic and
specifically recognized by canine VL (CVL) sera, whereas a Th1
response, induced by immunization of a combination of rLiHyp1
and saponin, was able to confer protection against L. infantum. This
protection correlated with a Leishmania antigens-specific and IL-12-
dependent IFN-c production, mediated mainly by CD4 T cells, as
well as by a diminished production of parasite-specific IL-4 and
IL-10.
Thus, the present study demonstrates that this unique
amastigote-specific protein, a member of the super-oxygenase
family in Leishmania, can be a new candidate for the improvement
of serodiagnosis of CVL and, when associated with a Th1-type
adjuvant, to develop an effective vaccine against VL.
Materials and Methods
Ethics statement
Experiments were performed in compliance with the National
Guidelines of the Institutional Animal Care, and Committee on
the Ethical Handling of Research Animals (CEUA) from the
Federal University of Minas Gerais (Law number 11.794, 2008),
with code number 043/2011. Sera samples used in this study were
kindly provided by Prof. Fernando Ae´cio de Amorim Carvalho
(Department of Pharmacology and Biochemistry, UFPI) and Prof.
Maria Norma Melo (Department of Parasitology, Institute of
Biological Sciences, UFMG).
Mice and parasites
Female BALB/c mice (8 weeks age) were obtained from the
breeding facilities of the Department of Biochemistry and
Immunology, Institute of Biological Sciences, UFMG, and were
maintained under specific pathogen-free conditions. Experiments
were carried out using the L. infantum (MOM/BR/1970/BH46)
strain. Parasites were grown at 24uC in Schneider’s medium
(Sigma, St. Louis, MO, USA), supplemented with 10% heat-
inactivated fetal bovine serum (FBS, Sigma), 20 mM L-glutamine,
200 U/mL penicillin, and 100 mg/mL streptomycin, at pH 7.4.
The soluble L. infantum antigenic extract (SLA) was prepared from
161010 stationary-phase promastigote cultures (5–7 day-old), as
described [17]. Parasites were kindly provided by Prof. Maria
Norma Melo.
Cloning of DNA sequence coding for L. infantum
hypothetical protein, LiHyp1
The LiHyp1 (XP_001468941.1) nucleotide and amino acid
sequences used in this study were obtained from the National
Center for Biotechnology Information (http//www.ncbi.nlm.nih.
gov). The local alignment of the LiHyp1 sequence against the
available complete genomes of other organisms was performed by
BLAST. Analyses of basic physical and chemical properties, as well
as phylogenetic analysis, were performed in a TriTrypDB database
(http://tritrypdb.org). The recombinant protein (rLiHyp1) was
obtained after having cloned a DNA L. infantum fragment containing
the LiHyp1 coding region. Initially, genomic DNA was extracted by
a phenol:chloroform extraction, as described [17], and it was used
as a template. Forward (59-GAAGGATCCAGCATGTCTATCG-
TGTCGAG-39) and reverse (59-GGAAAGCTTCGCTTGCGGC-
GTCACGTGAGC-39) primers were designed according to the
DNA sequence of the ORF described in the L. infantum genome
sequence database (LinJ.35.1290). The PCR product was cloned
Author Summary
Life-long immunity to leishmaniasis in recovered patients
has inspired the development of vaccines against disease.
The present study aimed to evaluate a non-described
hypothetical Leishmania amastigote-specific protein, iden-
tified by an immunoproteomic approach in L. infantum,
attempting to select a new candidate antigen for specific
serodiagnosis and a vaccine against visceral leishmaniasis
(VL). The recombinant protein (rLiHyp1) was recognized by
antibodies from sera of asymptomatic and symptomatic
canine visceral leishmaniasis (CVL), but presented no cross-
reactivity with sera of vaccinated dogs, those with Chagas’
disease or healthy animals. In addition, the rLiHyp1 plus
saponin was able to induce a Th1 response, which was
based on the production of high levels of IFN-c, IL-12, and
GM-CSF after in vitro stimulation in BALB/c mice. The
protective efficacy of rLiHyp1 plus saponin was evaluated
in mice challenged with L. infantum promastigotes.
Challenged and vaccinated mice showed significant
reductions in the number of parasites in all evaluated
organs, and the protection was associated with a Th1-type
response. Therefore, the present study reveals a new
potential candidate for the improvement of serodiagnosis
of CVL, as well as an effective vaccine candidate against VL.
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into the pGEM-T easy vector confirmed by sequencing and
transferred to the pET21a expression vector (Novagen), using the
BamHI and HindIII restriction enzymes included in the primers for
this purpose (underlined). Recombinant plasmid was transformed
into Escherichia coli BL21 (DE3). The recombinant protein expression
was performed by adding 0.5 mM IPTG (isopropyl-b-D-thioga-
lactopyranoside, Promega, Montreal, Canada) for 4 h at 37uC,
when cells were lysed by a homogenizer after five passages through
the apparatus. The product was centrifuged at 13.0006 g for
20 min at 4uC, while the rLiHyp1, containing a tag of 66 residues
of histidine, was purified under non-denaturing conditions, using a
5 mL HIS-Trap column (GE Healthcare Life Science) attached to
an FPLC (GE Healthcare Life Science) system. After purification,
the recombinant protein was passed through a polymyxin-agarose
column (Sigma) to remove residual endotoxin content.
Canine sera and ELISA for immunodiagnosis and
immunoblotting
To evaluate the antigenicity of rLiHyp1, sera samples from
healthy (n = 37), vaccinated with Leish-TecH (n = 18), T. cruzi
experimentally infected (n = 18), asymptomatic (n = 19) and
symptomatic L. infantum-infected dogs (n = 15) were used. All
animals were considered symptomatic when three or more of the
following symptoms were present: loss of weight, alopecia,
adenopathy, onychogryphosis, hepatomegaly, conjunctivitis and
exfoliate dermatitis on the nose, tail and ear tips; and asymptom-
atic when they were free from clinical symptoms. In the infected
animals, the diagnosis of the disease was defined when amastigotes
were seen in Giemsa stained smears of bone marrow aspirates or
promastigotes were identified on culture of peripheral blood or
bone marrow aspirates. Sera were considered positive when tested
by indirect immunofluorescence. A titration curve was performed
to determine the best protein concentration and antibody dilution
to perform ELISA. Plates (Falcon) were sensitized with rLiHyp1
(1.0 mg/well) or SLA (0.5 mg/well) for 18 h at 4uC. Free binding
sites were blocked with a PBS-Tween 20 0.05% (PBST) and 5%
casein solution for 2 h at 37uC. After five washes with PBST,
plates were incubated with 100 mL of canine sera for 1 h at 37uC.
Serum samples were diluted 1:200 in PBST and 0.5% casein.
After, plates were washed seven times with PBST and incubated
with 1:10.000 anti-dog IgG antibody (Sigma, St. Louis, USA)
horseradish peroxidase conjugated. The reaction was developed
through incubation with H2O2, along with orto-phenylenediamine
and citrate-phosphate buffer pH 5.0, for 30 min in the dark, and
was stopped by adding H2O2 2 N. Optical densities were read at
492 nm in an ELISA microplates spectrophotometer (Molecular
Devices, Spectra Max Plus, Concord, Canada).
For immunoblotting experiments, the recombinant protein was
submitted to a 10% SDS-PAGE and blotted onto a nitrocellulose
membrane (0.2 mm pore size, Sigma, St. Louis, USA). Membranes
were blocked with PBST and 5% casein solution, and were
incubated for 2 h at 37uC before the first incubation with a pool of
sera samples of asymptomatic CVL, diluted 1:100 in PBST.
Peroxidase conjugated anti-dog IgG (1:5.000) was used as a second
antibody (Sigma). Reactions were revealed by adding chloronaph-
tol, diaminobenzidine, and H2O2.
Immunization and challenge infection
Mice (n = 8, per group) were vaccinated subcutaneously in their
left hind footpad with 25 mg of rLiHyp1 associated with 25 mg of
saponin (Quillaja saponaria bark saponin, Sigma), with adjuvant or
only diluent (PBS). Three doses were administered at 2-week
intervals. Four weeks after the final immunization, animals (n = 4,
per group) were euthanized for the analysis of the immune
response elicited by vaccination. At the same time, the remaining
animals were infected subcutaneously in the right hind footpad,
with virulent 16107 stationary-phase promastigotes of L. infantum,
when 10 weeks after the animals were euthanized, and the liver,
spleen, bone marrow (BM), and the paws’ draining lymph nodes
(dLN) were collected to determine parasite burden and evaluation
of the immune response.
Estimation of parasite load
The liver, spleen, BM, and dLN were collected for parasite
quantification, following a limiting-dilution protocol [18]. Briefly,
the organs were weighed and homogenized using a glass tissue
grinder in sterile PBS. Tissue debris was removed by centrifuga-
tion at 1506 g, and cells were concentrated by centrifugation at
20006 g. Pellets were resuspended in 1 mL of Schneider’s insect
medium supplemented with 20% FBS. Two hundred and twenty
microliters were plated onto 96-well flat-bottom microtiter plates
(Nunc, NunclonH, Roskilde, Denmark) and diluted in log-fold
serial dilutions in supplemented Schneider’s medium with a 1021
to 10220 dilution. Each sample was plated in triplicate and read 7
days after the beginning of the culture at 24uC. Pipette tips were
discarded after each dilution to avoid carrying adhered parasites
from one well to another. Results are expressed as the negative log
of the titer (i.e., the dilution corresponding to the last positive well)
adjusted per microgram of tissue.
Cytokine production
Splenocyte cultures and cytokine assays were performed before
infection and at 10th week after challenge, as described [17].
Briefly, single-cell preparations from spleen tissue were plated in
duplicate in 24-well plates (Nunc) at 56106 cells per mL. Cells
were incubated in DMEM medium (non-stimulated, background
control), or separately stimulated with SLA (25 mg mL21) or
rLiHyp1 (20 mg mL21), at 37uC in 5% CO2 for 48 h. IFN-c, IL-4,
IL-10, IL-12, and GM-CSF levels were assessed in the superna-
tants by a sandwich ELISA provided in commercial kits (BD
OptEIA TM set mouse IFN-c (AN-18), IL-12 and GM-CSF;
Pharmingen, San Diego, CA, USA; and Murine IL-4 and IL-10
ELISA development kits; PeproTechH, Sa˜o Paulo, Brazil);
following manufacturer’s instructions. In order to block IL-12,
CD4, and CD8 mediated T cell cytokine release, spleen cells of
mice vaccinated with rLiHyp1 plus saponin and challenged with L.
infantum were in vitro stimulated with SLA (25 mg mL21), and
incubated in the presence of 5 mg mL21 of monoclonal antibodies
(mAb) against mouse IL-12 (C17.8), CD4 (GK 1.5), or CD8 (53-
6.7). Appropriate isotype-matched controls – rat IgG2a (R35-95)
and rat IgG2b (95-1) – were employed in the assays. Antibodies
(no azide/low endotoxinTM) were purchased from BD (Pharmin-
gen, San Diego, CA, USA).
Statistical analysis
The statistical analysis was made using the GraphPad Prism
software (version 5.0 for Windows). Statistical analysis with the
vaccinated and/or infected mice was performed by one-way
analysis of variance (ANOVA), using the Bonferroni’s post-test for
multiple comparisons of groups. Receiver Operating Character-
istic (ROC) curves were used to analyze the data obtained using
sera samples of dogs. Statistical analysis between CVL and the
control groups were performed by one-way ANOVA using
Tukey’s multiple comparison test. Differences were considered
significant when P,0.05. Data of shown in this study are
representative of two independent vaccination’ experiments,
which presented similar results.
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Results
Antigenicity of the L. infantum hypothetical protein,
LiHyp1
In the present study, a putative member of the super-oxygenase
family in Leishmania was fused as a recombinant protein to an N-
terminal 66 histidine-tag and expressed in E. coli. The recombi-
nant protein (rLiHyp1) was purified by nickel affinity chromatog-
raphy (Fig. 1A), and tested for serodiagnosis of CVL. Initially, a
pool of sera of asymptomatic dogs was able to recognize the
rLiHyp1 by immunoblotting analysis, as seen in Fig. 1B.
Sera were individually tested in ELISA against rLiHyp1, and
the results indicated that all sera samples of symptomatic dogs, and
18 out of 19 samples of asymptomatic CVL animals were able to
recognize the recombinant protein. In contrast, antibodies from T.
cruzi-infected, Leish-TecH vaccinated or healthy dogs did not react
with the rLiHyp1 protein (Fig. 1C). To determine the diagnostic
performance of rLiHyp1 for CVL, Receiver-Operating Charac-
teristic (ROC) curves were constructed to determine area under
curve (AUC) and sensitivity and specificity values in the
experiments. In the results, it was observed that the performance
of rLiHyp1 proved to be highly effective in order to identify sera
samples of symptomatic and asymptomatic CVL, and also to
differentiate them in relation to the other sera samples employed
in this study (Fig. 1D and 1E, respectively).
Immunogenicity and protective efficacy of rLiHyp1
against L. infantum
The immunogenicity of the rLiHyp1 was evaluated in BALB/c
mice, 4 weeks after the last vaccine dose. Following in vitro
stimulation with rLiHyp1, spleen cells from vaccinated mice
significantly produced higher levels of IFN-c, IL-12, and GM-CSF
than those secreted by spleen cells from control mice (saline and
saponin groups). No increase in IL-4 and IL-10 production could
be observed in any experimental group, after stimulation with
rLiHyp1 (Fig. 2A). The ratio between IFN-c/IL-4 and IFN-c/IL-
10 levels; as well as between IL-12/IL-4 and IL-12/IL-10 levels
showed that vaccinated animals presented an elevated Th1
immune response after rLiHyp1-stimulus (Fig. 2B and 2C,
respectively). In addition, mice vaccinated with rLiHyp1 plus
saponin presented an rLiHyp1-specific humoral response, with the
predominance of IgG2a isotype (Fig. 2D).
Next, the present study analyzed whether the immunization
with the rLiHyp1 plus saponin was able to induce protection
against L. infantum. The infection was followed up over a 10-weeks
period, when the parasite burden in the liver, spleen, BM, and
dLN was determined. Significant reductions in the number of
parasites were observed in the different evaluated organs of
vaccinated mice, as compared with those that received only saline
or saponin (Fig. 3). In this context, vaccinated mice with rLiHyp1
plus saponin showed significant reductions in the parasite load in
liver (3.8- and 3.3-log reductions, Fig. 3A), spleen (3.7- and 3.5-log
reductions, Fig. 3B), BM (3.0- and 3.0-log reductions, Fig. 3C),
and dLN (3.9- and 3.6-log reductions, Fig. 3D), in comparison to
the saline and saponin groups, respectively. Attempting to
determine the influence of immunization with rLiHyp1 plus
saponin on the L. infantum specific killing effectors functions in the
spleen of infected mice, nitrite was assayed as an indicator of nitric
oxide (NO) production in spleen cells. The nitrite production was
significantly higher in mice vaccinated with rLiHyp1 plus saponin
after stimulation with SLA, as compared to the control groups that
produced minimum amounts of this product (data not shown).
Cellular response elicited after L. infantum challenge
infection
The production of cytokines in the supernatants of spleen cells
cultures stimulated with rLiHyp1 and SLA after challenge was
analyzed to determine the immunological correlates of protection
induced by rLiHyp1. The spleen cells from mice vaccinated with
rLiHyp1 plus saponin produced higher levels of SLA-specific IFN-
c, IL-12 and GM-CSF cytokines than those secreted by spleen
cells from control groups, 10 weeks after infection (Fig. 4A). In
contrast, the SLA-driven production of IL-4 and IL-10 showed
that vaccination with rLiHyp1 plus saponin induced no produc-
tion of these cytokines in the vaccinated and infected animals.
The contribution of CD4 and CD8 T cells and the dependence
of IL-12 production for the SLA-specific IFN-c response from the
spleen cells of mice immunized with rLiHyp1 plus saponin and
challenged with L. infantum were evaluated. The IFN-c production
was completely suppressed using anti-IL-12 or anti-CD4 mono-
clonal antibodies in the spleen cells cultures (Fig. 4B). The addition
of anti-CD8 antibodies to the cultures also decreased the
production of IFN-c, as compared to the cell cultures without
treatment (1.8816139 pg/mL before, and 1.5336110 pg/mL
after including anti-CD8 antibodies); however, the production of
this cytokine proved to be higher than that produced by the use of
the anti-CD4 monoclonal antibody.
As observed before challenge, the ratio between IFN-c/IL-4
and IFN-c/IL-10, and between IL-12/IL-4 and IL-12/IL-10
indicated that vaccinated mice developed a specific Th1 immune
response, which was maintained after infection in these animals
(Fig. 4C and 4D, respectively). In this study, very low levels of anti-
SLA antibodies could be observed in the sera of all mice groups
challenged with L. infantum. However, it was possible to detect that
vaccinated and infected mice presented SLA-specific IgG2a
antibodies that were significantly higher than the obtained IgG1
levels (Fig. 4E).
Discussion
Different Leishmania proteins with antigenic properties were
recently identified by an immunoproteomic approach applied to L.
infantum promastigotes and amastigote-like proteic extracts [18],
including hypothetical proteins of the parasites. The fact that
antibodies present in the sera of infected dogs recognized these
hypothetical proteins indicates that they are expressed by parasites
during active infection, and are antigenic to the host’s immune
system. In this context, the DNA encoding one of these Leishmania
hypothetical proteins, which was specifically recognized by
antibodies in the amastigote-like antigenic extracts, was cloned
and expressed in E. coli and tested for its antigenicity and
prophylactic properties. Immunoblotting and ELISA analyses
demonstrated that the recombinant LiHyp1 protein (rLiHyp1) was
specifically recognized by antibodies present in the sera of dogs
with symptomatic and asymptomatic VL, yet it presented no cross-
reactivity with the sera of dogs vaccinated with a Brazilian
recombinant vaccine, Leish-TecH, or with animals experimentally
infected with T. cruzi, demonstrating, besides antigenicity its
potential for improvement of CVL serodiagnosis. Dogs are also
reservoirs for T. cruzi parasites in endemic areas for VL
transmission in Brazil, and seroprevalences of anti-T. cruzi
antibodies, which may cross react with Leishmania antigens, of
21.9% and up to 57.0% have been reported [19,20].
In a previous study, it was demonstrated that sera from dogs
naturally infected with L. infantum displayed reactivity with
Leishmania ribosomal proteins (LRP) through Western-Blot analy-
sis. A comparison between LRP and SLA showed that LRP had a
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Figure 1. Antigenicity of rLiHyp1 protein against canine sera. Ten micrograms of L. infantum SLA and of the rLiHyp1 protein were
electrophoresed on a SDS-PAGE 10% gel and stained with colloidal Coomassie Brilliant Blue G-250 (A). Western-Blot showing the reactivity against
the purified protein from a pool of sera from dogs with asymptomatic VL. Gels and Western-Blot used were derived from three independent
experiments, and one representative preparation was showed in this study (B). ELISA assays performed with rLiHyp1 (1 mg per well) against individual
Immune Competence of a Leishmania infantum Protein
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similar sensitivity in ELISA, but higher specificity than the SLA-
based assays in the diagnosis of CVL [21]. However, the technical
purification of LRP is complex and labor-intensive. In contrast,
the production of recombinant proteins is less complex and allows
obtain large amounts of proteins, when compared to production of
semi-purified extracts of the parasites (like LRP). In this context,
the use of the rLiHyp1 protein in the serodiagnosis of CVL is
attractive.
Amastigote antigens have been far less tested as vaccine
candidates against VL [15]. Therefore, a vaccine that is able to
elicit immune responses against intracellular amastigotes of
Leishmania may present advantages not only for prophylactic, but
also for therapeutic vaccines. In this context, the immunization
with rLiHyp1 plus saponin was able to induce a predominant Th1
immune response, which was characterized by an in vitro rLiHyp1-
specific production of IFN-c, IL-12 and GM-CSF, combined with
the presence of very low levels of IL-4 and IL-10. After infection,
mice immunized with rLiHyp1 plus saponin, when compared to
control groups, displayed significant reductions of the number of
parasites in all evaluated organs (liver, spleen, BM, and dLN),
which correlated a specific rLiHyp1- and SLA-dependent IFN-c
production in the spleen, one of the main cytokines implicated in
the acquired immunity against infection with Leishmania
[22,23,24]. The CD4 T cells proved to be the major source of
sera samples from healthy dogs (n = 37), T. cruzi-infected dogs (n = 18), Leish-TecH vaccinated animals (n = 18); and asymptomatic (n = 19) and
symptomatic (n = 15) L. infantum-infected dogs is showed (C). The OD values of each individual serum are shown. Cut-off value (dotted line) for
negative and positive samples discrimination was selected by Receiver-Operating Characteristic (ROC) curves analysis as the lower OD value with a
100% of specificity. Statistically significant differences were obtained between CVL groups and other groups: *** P,0.0001; and between the
symptomatic and asymptomatic groups: ### P,0.0001, by one-way ANOVA using the Tukey’s multiple comparison test. In order to analyze the
diagnostic performance of rLiHyp1 against different sera samples, ROC curves were used to determine area under curve (AUC) (D), and sensitivity and
specificity values (E).
doi:10.1371/journal.pntd.0002148.g001
Figure 2. Cellular and humoral response induced in BALB/c mice by immunization with rLiHyp1 plus saponin. Single cells suspensions
were obtained from the spleens of mice, four weeks after vaccination. Cells were non-stimulated (medium; background control) or stimulated with
rLiHyp1 (20 mg mL21) for 48 h at 37uC, 5% CO2. IFN-c, IL-12, GM-CSF, IL-4, and IL-10 levels were measured in culture supernatants by capture ELISA
(A). Each bar represents the mean 6 standard deviation (SD) of data from four individual mice per group. Statistically significant differences in the
IFN-c, IL-12 and GM-CSF levels between the rLiHyp1 plus saponin group and control mice (saline and saponin groups) were observed (*** P,0.0001).
The ratio between IFN-c/IL-10 and IFN-c/IL-4 levels (B); and between IL-12/IL-10 and IL-12/IL-4 levels (C) are also showed. Statistically significant
differences in the ratios between the rLiHyp1 plus saponin group and control groups were observed (*** P,0.0001). The ratio between rLiHyp1-
specific IgG1 and IgG2a antibodies was obtained for sera of each individual mouse within their respective vaccination group and statistically
significant difference between the rLiHyp1 plus saponin group and control groups was also observed (* P,0.005) (D).
doi:10.1371/journal.pntd.0002148.g002
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IFN-c in the protected mice, since depletion of these cells in
cultures of spleen cells stimulated with SLA significantly abrogated
this response. Similarly, in the vaccinated mice, IFN-c production
proved to be IL-12-dependent. Although previous reports have
shown that the activation of both CD4 and CD8 T cells subsets
may be important for the killing of parasites in mice vaccinated
with different parasite recombinant antigens [25,26], the present
study’s data suggest that CD8 T cells may contribute in a less
extension to the induction of IFN-c mediated response elicited by
the rLiHyp1 plus saponin formulation. Besides production of IFN-
c, these cells may contribute to infection control by their direct
cytotoxic effect on infected cells, as previously demonstrated in
other experimental conditions [24]. Altogether, the present study
indicates that immunization with rLiHyp1 plus saponin primed
BALB/c mice for an rLiHyp1-specific Th1 response that was
sustained after L. infantum infection challenge.
The present study also showed that the protection in BALB/c
mice against L. infantum is associated with a significant decrease in
the production of macrophage deactivating cytokines, like IL-4 and
IL-10. Very low levels of Leishmania-specific IL-10 were detected
after the stimulation of spleen cells from vaccinated mice, 10 weeks
after infection. In contrast, spleen cells from both control mice
groups showed a significantly higher production of this cytokine.
Indeed, control of the parasite-mediated IL-10 response in
vaccinated mice may be critical for protection, since this cytokine
is considered to be the most important factor for VL progression
after infection with viscerotropic Leishmania species in IL-10 deficient
mice [12,27,28], or in mice treated with an anti-IL-10 receptor
antibody [29]. In BALB/c mice, the IL-4-dependent production of
IgG1 antibodies is associated with disease progression due to some
Leishmania species, including L. amazonensis [30], but it is not
confirmed in L. infantum or L. donovani [31,32]. Nonetheless, in
BALB/c mice vaccinated with recombinant A2 protein or LRP plus
saponin, the protection against cutaneous or visceral leishmaniasis
have been also correlated with a decrease in Leishmania-specific IL-4
and IL-10 mediated response [12,17,22,33].
Spleen cells from vaccinated mice, as compared to the control
groups, produced higher levels of rLiHyp1- and SLA-specific GM-
CSF, a cytokine related with macrophage activation and resistance
in murine models against different intracellular pathogens,
including L. major [34], L. donovani [35], and L. chagasi ( = L.
infantum) [12]. It has also been shown that the immunization of
humans with a crude Leishmania antigenic preparation using this
cytokine as an adjuvant commonly induces a parasite-specific Th1
Figure 3. Protection of BALB/c mice vaccinated with rLiHyp1 plus saponin against L. infantum. Mice inoculated with saline, saponin, or
rLiHyp1 plus saponin were subcutaneously infected with virulent 16107 stationary-phase promastigotes of L. infantum. The number of parasites in
the liver (A), spleen (B), bone marrow (C), and paws’ draining lymph nodes (D) was measured, 10 weeks after challenge by a limiting-dilution
technique. Mean 6 standard deviation (SD) of four mice in each group is shown. Statistically significant differences in the parasite load in all
evaluated organs between the rLiHyp1 plus saponin group and control mice (saline and saponin groups) are showed (in numbers). Data shown in
this study are representative of two independent experiments, which presented similar results.
doi:10.1371/journal.pntd.0002148.g003
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response [36], and that the administration of a therapeutic vaccine
containing some Leishmania antigens plus GM-CSF could be
correlated with the cure of lesions in the muco-cutaneous
leishmaniasis [37].
A critical aspect for Leishmania vaccines development refers to
the pre-clinical model chosen for initial screening of vaccine
candidates. Although sand fly transmitted infection in hamsters
more closely resemble the natural transmission and the human
disease, this infection model requires specific laboratory conditions
and trained personnel staff, which are not widely available,
hindering its general use as a first step for testing vaccine efficacy
against VL [38]. In contrast, BALB/c mice infected with L. donovani
or L. infantum is one the most widely studied murine models for VL,
and is therefore naturally selected over other models for this purpose
[17,39,40,41]. Murine models have also allowed the characteriza-
tion of the immune mechanisms required to develop organ-specific
immune response against Leishmania [41,42]. Therefore, the
evaluation of the parasite burden in different organs is an important
marker of vaccine efficacy against VL in these models. In a recent
study, it was demonstrated that the subcutaneous route of
inoculation of L. infantum in BALB/c mice induces a faster infection
development in the animals and higher parasite burden in different
tissues as compared to the intravenous challenge [41]. In this
context, the subcutaneous route was selected to evaluate the efficacy
of rLiHyp1 plus saponin vaccine against L. infantum. In addition, in
comparative studies, it was found that protection afforded by
vaccination might be improved in animals challenged by intrader-
mal/subcutaneous route as compared to those receiving an
intravenous challenge [43,44]. Nevertheless, additional studies
may well be carried out in order to extend the observations present
herein of the protective efficacy of rLiHyp1 plus saponin
vaccination to other infection models and experimental conditions.
In conclusion, the present study’s data indicated that a
Leishmania amastigote-specific protein, member of the super-
oxygenase family, LiHyp1, is antigenic in the CVL, and also
conferred protection in BALB/c mice against L. infantum.
Protection correlated with the CD4 T cells response characterized
by high IFN-c, IL-12, and GM-CSF, and low IL-4 and IL-10
levels. Therefore, the LiHyp1 protein constitutes a new and
promising antigen candidate for serodiagnosis and vaccine
development against VL.
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Figure 4. Analysis of the cellular and humoral response and of the involvement of IL-12, CD4 and CD8 T cells in the IFN-c
production after L. infantum challenge. Single cells suspensions were obtained from the spleens of mice, 10 weeks after infection. Cells were
non-stimulated (medium; background control) or stimulated with L. infantum SLA (25 mg mL21) for 48 h at 37uC, 5% CO2. Levels of IFN-c, IL-12, GM-
CSF, IL-4 and IL-10 were measured in culture supernatants by capture ELISA. Mean 6 standard deviation (SD) of the cytokines levels determined in
four individual mice per group is shown (A). Statistically significant differences between the rLiHyp1 plus saponin group and the control mice (saline
and saponin groups) were observed (*** P,0.0001). The analysis of the involvement of IL-12 and CD4 and CD8 T cells in the IFN-c production is
showed (B). Levels of IFN-c in the supernatants of spleen cells cultures stimulated with SLA, as explained above, in the absence (positive control) or in
the presence of anti-IL-12, anti-CD4, or anti-CD8 monoclonal antibodies were measured. Statistically significant differences between non-treated
control cells and cultures incubated with anti-CD4 and anti-IL-12 monoclonal antibodies were observed (*** P,0.0001). The ratio between IFN-c/IL-10
and IFN-c/IL-4 levels (C), and between IL-12/IL-10 and IL-12/IL-4 levels (D), are also showed. Statistically significant differences between the rLiHyp1
plus saponin group and the control groups were observed (***P,0.0001). The ratio between SLA-specific IgG1 and IgG2a antibodies levels were
calculated for sera of each individual mouse within their respective vaccination group and statistically significant difference between the rLiHyp1 plus
saponin group and the control groups was also observed (* P,0.005) (E).
doi:10.1371/journal.pntd.0002148.g004
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